RT (10mg)

A next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors, currently being investigated in advanced clinical studies related to obesity and metabolic health. Research is focused on its potential role in appetite control, insulin response, and lipid metabolism through multi-receptor pathway activity.